- Home
- STEC vs ALXO Comparison
STEC vs ALXO Comparison
Compare STEC & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEC
- ALXO
- Stock Information
- Founded
- STEC 2006
- ALXO 2015
- Country
- STEC China
- ALXO United States
- Employees
- STEC N/A
- ALXO N/A
- Industry
- STEC
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- STEC
- ALXO Health Care
- Exchange
- STEC NYSE
- ALXO Nasdaq
- Market Cap
- STEC 29.7M
- ALXO 24.0M
- IPO Year
- STEC 2021
- ALXO 2020
- Fundamental
- Price
- STEC $0.97
- ALXO $0.48
- Analyst Decision
- STEC
- ALXO Strong Buy
- Analyst Count
- STEC 0
- ALXO 6
- Target Price
- STEC N/A
- ALXO $3.30
- AVG Volume (30 Days)
- STEC 12.1K
- ALXO 397.6K
- Earning Date
- STEC 07-01-2025
- ALXO 08-07-2025
- Dividend Yield
- STEC N/A
- ALXO N/A
- EPS Growth
- STEC N/A
- ALXO N/A
- EPS
- STEC N/A
- ALXO N/A
- Revenue
- STEC $28,023,000.00
- ALXO N/A
- Revenue This Year
- STEC $9,392.20
- ALXO N/A
- Revenue Next Year
- STEC N/A
- ALXO N/A
- P/E Ratio
- STEC N/A
- ALXO N/A
- Revenue Growth
- STEC 50.79
- ALXO N/A
- 52 Week Low
- STEC $0.20
- ALXO $0.41
- 52 Week High
- STEC $3.25
- ALXO $8.78
- Technical
- Relative Strength Index (RSI)
- STEC 43.73
- ALXO 44.63
- Support Level
- STEC $0.97
- ALXO $0.48
- Resistance Level
- STEC $1.02
- ALXO $0.59
- Average True Range (ATR)
- STEC 0.08
- ALXO 0.05
- MACD
- STEC 0.00
- ALXO -0.00
- Stochastic Oscillator
- STEC 14.78
- ALXO 8.75
About STEC SANTECH HOLDINGS LIMITED
Santech Holdings Ltd is a customer based technology company. The company is engaged in exploring new opportunities in technology that includes new retail, social e-commerce, metaverse and others.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.